Actuate Therapeutics, Inc. $ACTU Shares Purchased by Voss Capital LP

Voss Capital LP boosted its stake in Actuate Therapeutics, Inc. (NASDAQ:ACTU) by 45.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,300,000 shares of the company’s stock after buying an additional 403,722 shares during the period. Voss Capital LP owned 0.06% of Actuate Therapeutics worth $7,956,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ACTU. ABS Direct Equity Fund LLC acquired a new stake in Actuate Therapeutics in the fourth quarter worth $40,000. Deutsche Bank AG increased its position in Actuate Therapeutics by 640.0% in the fourth quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after buying an additional 8,051 shares during the period. Bank of America Corp DE increased its position in Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after buying an additional 15,267 shares during the period. Jane Street Group LLC acquired a new stake in Actuate Therapeutics in the fourth quarter worth $102,000. Finally, New York State Common Retirement Fund bought a new position in shares of Actuate Therapeutics in the second quarter worth $105,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen lowered Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Friday, March 27th. Finally, HC Wainwright reissued a “buy” rating on shares of Actuate Therapeutics in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.50.

Actuate Therapeutics Stock Performance

Shares of ACTU opened at $2.02 on Friday. The firm has a market capitalization of $48.34 million, a price-to-earnings ratio of -2.08 and a beta of 0.52. Actuate Therapeutics, Inc. has a one year low of $1.58 and a one year high of $9.22. The stock’s fifty day moving average is $2.38 and its 200-day moving average is $4.08.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Analysts forecast that Actuate Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.

Actuate Therapeutics Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.